For advanced and non-resectable BRAF-mutant cutaneous melanoma, combination BRAF/MEK inhibitors produce high initial response rates and at least a partial objective response in most patients, with only mild toxicity. The gene discussed is BRAF; the disease is cutaneous melanoma.